Tumor mutational burden-high solid malignant tumor

Tumor mutational burden-high solid malignant tumor is a tissue-agnostic oncologic indication describing non-hematologic cancers that harbor an elevated frequency of somatic genomic mutations Arising in diverse anatomic sites across adult and pediatric populations, these neoplasms are defined by a high mutation density—frequently established as ten or more mutations per megabase through validated genomic sequencing

Tumor mutational burden-high solid malignant tumor is a tissue-agnostic oncologic indication describing non-hematologic cancers that harbor an elevated frequency of somatic genomic mutations Arising in diverse anatomic sites across adult and pediatric populations, these neoplasms are defined by a high mutation density—frequently established as ten or more mutations per megabase through validated genomic sequencing This enhances cellular immunogenicity and renders the malignant tissue uniquely re...

Pathophysiologically, the substantial burden of non-synonymous mutations generates an increased repertoire of tumor-specific neoantigens This enhances cellular immunogenicity and renders the malignant tissue uniquely recognizable to host tumor-infiltrating lymphocytes, frequently underlying heightened susceptibility to immune checkpoint pathway modulation